Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics.
about
Blood-Based Proteomic Biomarkers of Alzheimer's Disease PathologyThe association of depression, cognitive impairment without dementia, and dementia with risk of ischemic stroke: a cohort study.Upregulation of glycolytic enzymes, mitochondrial dysfunction and increased cytotoxicity in glial cells treated with Alzheimer's disease plasma.Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease.Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms.Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's diseaseQuantitative Proteomics Reveals the Mechanism of Oxygen Treatment on Lenses of Alzheimer's Disease Model Mice.Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease.Time-course global proteome analyses reveal an inverse correlation between Aβ burden and immunoglobulin M levels in the APPNL-F mouse model of Alzheimer disease.iTRAQ-based Proteomic Analysis of APPSw,Ind Mice Provides Insights into the Early Changes in Alzheimer's Disease.Analysis of the plasma proteome using iTRAQ and TMT-based Isobaric labeling.Evolving Relevance of Neuroproteomics in Alzheimer's Disease.A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication.Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease.Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias
P2860
Q26774743-40F175E4-42C6-4A7C-A0FA-5F924F76EEBDQ35096747-94FBD100-0748-46A5-BD2F-5BBCD7FC15B6Q35191570-77C98FC9-55C3-4F1A-8F11-32BD20038227Q36256076-3753AAC5-ADB5-480E-9DCA-0603CD033CFCQ36409186-087CF513-2DA3-475D-A4FA-2F4A9735D601Q37067687-CE5E94D8-0A86-4B37-9CF4-54BBC0A014D4Q38443454-8805B51C-B630-4445-892C-F5B09D060B51Q39451611-167F052F-C045-46DA-83C5-8320AACBB70DQ39620255-84106F9F-363F-417A-B673-8D023EEF2096Q41498857-6E502C75-0240-4677-BD52-EFBB5691399BQ47104812-397BDA85-E1D4-4EEE-9BD6-602FCB3A84AFQ47421750-259BF85A-D24F-4EA5-90CF-8BF16866F10EQ50999408-F435D15C-38E6-482F-97D1-5170A088132EQ51760901-5914C10E-1E58-4977-892B-977E14B3DF27Q55293538-330AB2C5-83A5-41C2-8AA4-0352F54C79DFQ58779295-D3076EE9-66C1-4684-BA65-52E80621F714
P2860
Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plasma protein profiling of Mi ...... iTRAQ quantitative proteomics.
@en
Plasma protein profiling of Mi ...... iTRAQ quantitative proteomics.
@nl
type
label
Plasma protein profiling of Mi ...... iTRAQ quantitative proteomics.
@en
Plasma protein profiling of Mi ...... iTRAQ quantitative proteomics.
@nl
prefLabel
Plasma protein profiling of Mi ...... iTRAQ quantitative proteomics.
@en
Plasma protein profiling of Mi ...... iTRAQ quantitative proteomics.
@nl
P2093
P2860
P356
P1433
P1476
Plasma protein profiling of Mi ...... iTRAQ quantitative proteomics.
@en
P2093
Anne Poljak
George A Smythe
Mark Raftery
Nicole A Kochan
P2860
P2888
P356
10.1186/1477-5956-12-5
P577
2014-01-17T00:00:00Z
P5875
P6179
1004509502